colistimethate sodium has been researched along with ciprofloxacin in 1 studies
Studies (colistimethate sodium) | Trials (colistimethate sodium) | Recent Studies (post-2010) (colistimethate sodium) | Studies (ciprofloxacin) | Trials (ciprofloxacin) | Recent Studies (post-2010) (ciprofloxacin) |
---|---|---|---|---|---|
188 | 12 | 140 | 16,060 | 1,331 | 6,092 |
Protein | Taxonomy | colistimethate sodium (IC50) | ciprofloxacin (IC50) |
---|---|---|---|
Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | 0.41 | |
DNA gyrase subunit B | Bacillus subtilis subsp. subtilis str. 168 | 6.3 | |
DNA gyrase subunit A | Bacillus subtilis subsp. subtilis str. 168 | 6.3 | |
Cytochrome P450 3A4 | Homo sapiens (human) | 0.31 | |
DNA gyrase subunit B | Staphylococcus aureus | 4.32 | |
DNA gyrase subunit A | Escherichia coli K-12 | 0.6845 | |
DNA gyrase subunit B | Escherichia coli K-12 | 0.5632 | |
DNA topoisomerase 4 subunit B | Staphylococcus aureus | 6.485 | |
DNA topoisomerase 4 subunit A | Staphylococcus aureus | 4.8011 | |
Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | 0.41 | |
Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | 0.41 | |
Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | 0.41 | |
Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | 0.41 | |
Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 0.41 | |
DNA gyrase subunit A | Staphylococcus aureus | 4.32 | |
Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | 0.41 | |
Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 0.41 | |
Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | 0.41 | |
Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | 0.41 | |
Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | 0.41 | |
Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.41 | |
Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | 0.41 | |
Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | 0.41 | |
DNA topoisomerase 4 subunit A | Bacillus subtilis subsp. subtilis str. 168 | 1.7 | |
DNA topoisomerase 4 subunit B | Bacillus subtilis subsp. subtilis str. 168 | 1.7 | |
GABA theta subunit | Rattus norvegicus (Norway rat) | 0.41 | |
Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | 0.41 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cho, E; Davidson, AG; Lillquist, YP | 1 |
1 other study(ies) available for colistimethate sodium and ciprofloxacin
Article | Year |
---|---|
Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009.
Topics: Administration, Oral; Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Burkholderia cepacia complex; Child; Child, Preschool; Ciprofloxacin; Cohort Studies; Colistin; Cystic Fibrosis; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Health Care Costs; Health Resources; Humans; Infant; Injections, Intravenous; Nebulizers and Vaporizers; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome | 2011 |